key: cord-0716493-r25lif6d
authors: Saito, Akatsuki; Irie, Takashi; Suzuki, Rigel; Maemura, Tadashi; Nasser, Hesham; Uriu, Keiya; Kosugi, Yusuke; Shirakawa, Kotaro; Sadamasu, Kenji; Kimura, Izumi; Ito, Jumpei; Wu, Jiaqi; Iwatsuki-Horimoto, Kiyoko; Ito, Mutsumi; Yamayoshi, Seiya; Ozono, Seiya; Butlertanaka, Erika P; Tanaka, Yuri L; Shimizu, Ryo; Shimizu, Kenta; Yoshimatsu, Kumiko; Kawabata, Ryoko; Sakaguchi, Takemasa; Tokunaga, Kenzo; Yoshida, Isao; Asakura, Hiroyuki; Nagashima, Mami; Kazuma, Yasuhiro; Nomura, Ryosuke; Horisawa, Yoshihito; Yoshimura, Kazuhisa; Takaori-Kondo, Akifumi; Imai, Masaki; Nakagawa, So; Ikeda, Terumasa; Fukuhara, Takasuke; Kawaoka, Yoshihiro; Sato, Kei
title: SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity
date: 2021-07-19
journal: bioRxiv
DOI: 10.1101/2021.06.17.448820
sha: 25af8a82990d0475e0127bf812cf8c7edf24db60
doc_id: 716493
cord_uid: r25lif6d

During the current SARS-CoV-2 pandemic, a variety of mutations have been accumulated in the viral genome, and currently, four variants of concerns (VOCs) are considered as the hazardous SARS-CoV-2 variants to the human society1. The newly emerging VOC, the B.1.617.2/Delta variant, closely associates with a huge COVID-19 surge in India in Spring 20212. However, its virological property remains unclear. Here, we show that the B.1.617.2/Delta variant is highly fusogenic, and notably, more pathogenic than prototypic SARS-CoV-2 in infected hamsters. The P681R mutation in the spike protein, which is highly conserved in this lineage, facilitates the spike protein cleavage and enhances viral fusogenicity. Moreover, we demonstrate that the P681R-bearing virus exhibits higher pathogenicity than the parental virus. Our data suggest that the P681R mutation is a hallmark that characterizes the virological phenotype of the B.1.617.2/Delta variant and is closely associated with enhanced pathogenicity.

cluster, respectively (Fig. 1a, Extended Data Fig. 1) . We then analyzed the 116 epidemic of each of three B.1.617 sublineages. The B.1.617 variant, particularly 117 B.1.617.1, was first detected in India on December 1, 2020 (GISAID ID: 118 EPI_ISL_1372093) (Fig. 1b-d) . Note that a SARS-CoV-2 variant (GISAID ID: 119 EPI_ISL_2220643) isolated in Texas, the USA, on August 10, 2020, was also 120 recorded to belong to the B. December 10, 2020 and February 13, 2021, respectively (Fig. 1e, f) . The B.1.617.1 129 sublineage has peaked during February to April, 2021, in India, and then decreased 130 (Fig. 1d) . Although the B.1.617.3 variant has sporadically detected in India (Fig. 1f) , 131 the B.1.617.2/Delta lineage has become dominant in India since March 2021 and 132 spread all over the world (Fig. 1e) . At the end of May 2021, 100%, 70% and 43.3% 133 of the deposited sequences in GISAID per day from India (May 7), the UK (May 21) 134 and the whole world (May 19) have been occupied by the B.1.617.2 sublineage (Fig. 135 1e and Extended Data Table 1) . 136 We next investigated the proportion of amino acid replacements in the S 137 protein of each B.1.617 sublineage comparing with the reference strain (Wuhan-Hu-138 1; GenBank accession no. NC_045512.2). As shown in Fig. 1g was significantly lower than that of the B.1.1 isolate (Fig. 2a) . Particularly, the levels 150 of viral RNA of the B.1.617.2/Delta variant at 48 hours postinfection (hpi) was more 151 than 150-fold lower than that of the B.1.1 isolate (Fig. 2a) . On the other hand, 152

although the growth kinetics of these viruses was relatively comparable in 153

VeroE6/TMPRSS2 cells and Calu-3 cells (Fig. 2a) , microscopic observations 154

showed that the B.1.617.2/Delta formed larger syncytia compared to the B.1.1 virus 155 (Fig. 2b) . By measuring the size of the floating syncytia in the infected 156

VeroE6/TMPRSS2 culture, the syncytia formed by the B.1.617.2/Delta infection 157

were significantly (2.7-fold) larger than that by the B.1.1 infection (Fig. 2b) . 158 Immunofluorescence assay further showed that the B.1.617.2/Delta-infected 159

VeroE6/TMPRSS2 cells exhibit larger multinuclear syncytia compared to the B.1.1 160 isolate (Extended Data Fig. 2) . These results suggest that the B. Although the viral RNA loads in the oral swab of the B.1.617.2/Delta-infected 167 hamsters were significantly lower than those of the B.1.1-infected hamsters at 1 and 168 4 days postinfection (dpi), these values were comparable any other dpi (Fig. 2c) .

After infection with these viruses, infected hamsters significantly lost their body 170

weights from 2 dpi. The peak weight loss was 16% for the B. (Fig. 1g) . Because the P681R mutation is 179 located in the proximity of the furin cleavage site (FCS; residues RRAR positioned 180 between 682-5) of the SARS-CoV-2 S protein 19 , we hypothesized that the P681R 181 mutation is responsible for the preference of cell-cell fusion, which leads to larger 182 syncytia formation. To address this possibility, we generated the P681R-bearing 183 artificial virus by reverse genetics (Extended Data Fig. 3 ) and preformed virological 184 experiments. Although the amounts of viral RNA in the culture supernatants of the 185 D614G/P681R-infected Vero and VeroE6/TMPRSS2 cells were significantly lower 186 than those of the D614G-infected cells in some time points, the growth of these two 187 viruses was relatively comparable (Fig. 3a) . However, the size of floating syncytia in 188 the D614G/P681R-infected VeroE6/TMPRSS2 cells at 72 hpi was significantly larger 189 than that in the D614G mutant-infected cells (Fig. 3b) . This observation well 190 corresponds to that in the culture infected with the B.1.617.2/Delta variant (Fig. 2b) .

To clearly observe the syncytia formation, we further generated the expressing replication-competent D614G and D614G/P681R viruses. The levels of 193 viral RNA in the supernatant and GFP-positive cells were similar in Vero, 194 VeroE6/TMPRSS2 and Calu-3 cells (Extended Data Fig. 4) Fig. 6b) . These data suggest that the P681R mutation 217

does not affect the infectivity of viral particles. 218 We next addressed the effect of P681R mutation on viral fusogenicity by 219 cell-based fusion assay. In the effector cells (i.e., S-expressing cells), although the 220 expression level of the D614G/P681R S protein was comparable to that of the 221 D614G S, the level of the cleaved S2 subunit of the D614G/P681R mutant was 222 significantly higher than that of the D614G S (Fig. 3d) . Consistent with the results in 223 the pseudovirus assay (Extended Data Fig. 6) , these results suggest that P681R 224 mutation facilitates the S cleavage. Flow cytometry showed that the surface 225 expression level of the D614G/P681R S was significantly lower than the D614G S 226 (Extended Data Fig. 7) . Nevertheless, the cell-based fusion assay using the target 227 cells without TMPRSS2 demonstrated that the D614G/P681R S is 2.1-fold more 228 fusogenic than the D614G S with a statistical significance (P = 0.0002 by Welch's t 229 test) (Fig. 3e) . Moreover, a mathematical modeling analysis of the fusion assay data 230

showed that the initial fusion velocity of the D614G/P681R S (0.83 ± 0.03 per hour) 231 is significantly (2.8-fold) faster than that of the D614G S (0.30 ± 0.03 per hour; P = 232 4.0 × 10 -6 by Welch's t test) (Fig. 3f, g) . These data suggest that the P681R mutation 233 enhances and accelerates the SARS-CoV-2 S-mediated fusion. Furthermore, when 234

we use the target cells with TMPRSS2 expression, both the fusion efficacy (~1.2-235 fold) and initial fusion velocity (~2.0-fold) were increased in both the D614G and 236 D614G/P681R S proteins (Fig. 3f, g) . These results suggest that TMPRSS2 237 facilitates the fusion mediated by SARS-CoV-2 S and human ACE2, while the 238 TMPRSS2-dependent acceleration and promotion of viral fusion is not specific for 239 the P681R mutant. 240 241

Resistance to NAb-mediated antiviral immunity by the P681R mutation 242

The resistance to the NAb in the sera of COVID-19 convalescents and vaccinated 243 individuals is a hallmark characteristic of the VOCs (reviewed in 20,21 ), and it has 244 been recently showed that the B. Extended Data Fig. 8b and 9) . These results suggest that the P681R-bearing 254 pseudovirus is relatively resistant to NAbs. Notably, in contrast to the neutralising 255 activity against cell-free viruses, the SARS-CoV-2 S-based fusion assay showed that 256 cell-cell infection is strongly resistant to the NAbs and the insensitivity to the NAbs 257 on cell-cell infection is not dependent on the P681R mutation (Extended Data Fig.  258 8c). Altogether, these findings suggest that the P681R mutation confers the NAbs 259 resistance upon cell-free viral particles and cell-cell infection is resistant to the NAb-260 mediated antiviral action compared to cell-free infection. 261 262 P681R mutation as the determinant of higher pathogenicity of the Delta variant 263

To assess the impact of the P681R mutation on viral replication and the 264 pathogenicity of SARS-CoV-2, Syrian hamsters were intranasally infected with the 265 D614G and D614G/P681R viruses. The D614G-infected hamsters exhibited no 266 weight loss, although a slight decrease in body weight was observed for one of the 267 animals by 7 dpi (5.0%) (Fig. 4a) . In contrast, all of hamsters infected with the 268 D614G/P681R virus experienced a gradual body weight loss and the animals 269 showed a significant weight loss of 4.7-6.9% at 7 dpi compared to the D614G virus 270 (P = 0.011, Fig. 4a ). We also assessed pulmonary function in infected hamsters by 271 measuring enhanced pause (PenH), which is a surrogate marker for 272 bronchoconstriction or airway obstruction, by using a whole-body plethysmography 273

system. Syrian hamsters infected with the D614G and D614G/P681R viruses 274

showed the increases in the lung PenH value ( Fig. 4b) . At 7 dpi, the D614G/P681R-275 infected animals had significantly higher PenH values compared with those of the 276 D614G-infected animals (P = 0.043). At 3 dpi, both viruses replicated efficiently in 277 the lungs and nasal turbinates of the infected animals and no significant difference 278 in viral replication was observed between the two groups ( Fig. 4c) . At 7 dpi, no 279 differences in viral titres in the nasal turbinates were found between the two groups; 280 however, the lung titres in the D614G/P681R-infected group were significantly higher 281 than those in the D614G-infected groups (P = 0.0013, Fig. 4c ).

Discussion 284

Previous studies have demonstrated the close association of the FCS in the SARS-285

CoV-2 S protein with viral replication mode and it is dependent on TMPRSS2. P681R mutation that is highly conserved in this lineage enhances the efficacy of viral 300 fusion and further accelerates its speed of action. The P681R-mediated rapid 301 kinetics of viral fusion may attribute to not only immune evasion but also possibly 302 feasible the infection to exposed individuals. 303

Consistent with previous reports 25, 26 , here we showed that the cell-cell 304 infection mediated by the SARS-CoV-2 S protein is resistant to NAbs. The effect of 305

NAbs against cell-cell infection has been well studied in HIV-1 (Retroviridae) 306

infection, and it is well known that cell-cell infection is relatively more resistant to 307

NAbs compared to cell-free infection (reviewed in [27] [28] [29] were inoculated and the copy number of viral RNA in the culture supernatant was 567 quantified by real-time RT-PCR. The growth curves of the viruses inoculated are 568

shown. Assays were performed in quadruplicate. infected with 10 5 TCID50 of the B.1.1 isolate (n = 6) and the B.1.617.2/Delta isolate 577 (n = 12). Four hamsters at the same age were used for mock infection. The amount 578 of viral RNA in the oral swab (c) and body weight (d) and were routinely measured. 579

In a, statistically significant differences (*, P < 0.05) versus the B.1.1 isolate were 580 determined by Student's t test. NS, no statistical significance. 581

In b, statistically significant differences versus the B.1.1-infected culture (*, P < 0.05) 582

and uninfected culture (#, P < 0.05) were determined by the Mann-Whitney U test. 583

In c and d, statistically significant differences were determined by the Mann-Whitney 584 U test, and those versus uninfected hamsters (*, P < 0.05) are indicated by asterisks. 585

The P value between the B.1.1 and the B.1.617.2/Delta at each dpi is indicated in 586 the figure. In b,c, statistically significant differences versus the D614G mutant-infected culture 617 (*, P < 0.05) and uninfected culture (#, P < 0.05) were determined by the Mann-618

Whitney U test. 619

In d, a statistically significant difference (*, P < 0.05) versus the D614G S was 620 determined by Student's t test. 621

In g, statistically significant differences (*, P < 0.05) were determined by two-sided 622

Welch Extended Data Fig. 8 . Association of the P681R mutation on the sensitivity to 721

NAbs.

Neutralisation assay was performed by using three RBD-targeting monoclonal 723

antibodies (clones 8A5, 4A3 and CB6) (a and c) and 19 vaccinated sera (b). NAbs 724

were used for the pseudovirus assay (a and b) and the S-based fusion assay (c). 725

Pseudoviruses and effector cells (S-expressing cells) were treated with serially 726 diluted NAbs or sera as described in Methods. The raw data of panel b is shown in 727

Extended Data Fig. 9 . NT50, 50% neutralisation titre. 728

In a, the NT50 values of the D614G S (black) and D614G/P681R S (orange) are 729

indicated. 730

In b, a statistically significant difference versus the D614G virus was determined by 731

Wilcoxon matched-pairs signed rank test. 732 infected with the D614G or the D614G/P681R viruses (10 4 TCID50 in 30 μl); at 3 and 802 7 dpi, the animals were euthanized and nasal turbinates and lungs were collected. 803

The virus titers in the nasal turbinates and lungs were determined by use of plaque 804 assays on VeroE6/TMPRSS2 cells. 805 806

Lung function 807

Respiratory parameters were measured by using a whole-body plethysmography 808 system (PrimeBioscience) according to the manufacturer's instructions. In brief, 809 hamsters were placed in the unrestrained plethysmography chambers and allowed 810

to acclimatize for 1 m before data were acquired over a 3-min period by using 811

FinePointe software. 812 813 Viral Genomes 814

All SARS-CoV-2 genome sequences and annotation information used in this study 815

were downloaded from GISAID (https://www.gisaid.org) as of May 31, 2021 816

(1,761,037 sequences). We first excluded the genomes with non-human hosts. We 817 obtained SARS-CoV-2 variants belonging to the B. Scientific, Cat# H3570). The coverslips were mounted on glass slides using 900

Fluoromount-G (Southern Biotechnology, Cat# 0100-01) with Hoechst 33342. 901

Fluorescence microscopy was performed on a confocal laser microscope (A1RSi, 902

Nikon) and captured with NIS-Elements AR software (Nikon). The area of N-positive 903 cells was quantified using Fiji software implemented in Image J. 904 905 SARS-CoV-2 Reverse Genetics 906

Recombinant SARS-CoV-2 was generated by circular polymerase extension 907 reaction (CPER) as previously described 39, 43 . In brief, 9 DNA fragments encoding 908 the partial genome of SARS-CoV-2 (strain WK-521, PANGO lineage A; GISAID ID: 909 EPI_ISL_408667) 37 were prepared by PCR using PrimeSTAR GXL DNA polymerase 910 (Takara, cat# R050A). A linker fragment encoding hepatitis delta virus ribozyme, 911

bovine growth hormone polyA signal and cytomegalovirus promoter was also 912 prepared by PCR. The corresponding SARS-CoV-2 genomic region and the 913 templates and primers of this PCR are summarized in Extended Data Table 3. The  914 10 obtained DNA fragments were mixed and used for CPER 39 . To prepare the GFP-915 expressing replication-competent recombinant SARS-CoV-2, the fragment 9 in 916 which the GFP gene was inserted in the ORF7a frame was used instead of the 917 authentic F9 fragment (see Extended Data Table 3 ) 39 . 918

To produce recombinant SARS-CoV-2, the CPER products were 919 transfected into HEK293-C34 cells using TransIT-LT1 (Takara, cat# MIR2300) 920

according to the manufacturer's protocol. At one day posttransfection, the culture 921 medium was replaced with Dulbecco's modified Eagle's medium (high glucose) 922

(Sigma-Aldrich, cat# R8758-500ML) containing 2% FCS, 1% PS and doxycycline (1 923 μg/ml; Takara, cat# 1311N). At six days posttransfection, the culture medium was 924 harvested and centrifuged, and the supernatants were collected as the seed virus. 925

To remove the CPER products (i.e., SARS-CoV-2-related DNA), 1 ml of the seed 926 virus was treated with 2 μl TURBO DNase (Thermo Fisher Scientific, cat# AM2238) 927 and incubated at 37°C for 1 h. Complete removal of the CPER products (i.e., SARS-928

CoV-2-related DNA) from the seed virus was verified by PCR. The working virus was 929 prepared by using the seed virus as described above. 930

To generate recombinant SARS-CoV-2 mutants, mutations were inserted 931 in fragment 8 (Extended Data Table 3 ) using the GENEART site-directed 932 mutagenesis system (Thermo Fisher Scientific, cat# A13312) according to the 933 manufacturer's protocol with the following primers: Fragment 8_S D614G forward, 934

Extended Data Fig. 3. Chromatograms of the mutated regions of SARS-CoV-2 666 viruses artificially generated by reverse genetics

(right) of parental SARS-CoV-2 (strain WK-521

Extended Data Fig. 4. Growth kinetics of artificially generated GFP-expressing 674 viruses

These viruses (100 TCID50 for Vero and VeroE6/TMPRSS2 cells, 677 100 or 1,000 TCID50 for Calu-3 cells) were inoculated. The copy number of viral RNA 678 in the culture supernatant (a) and the level of GFP-positive cells (the percentage of 679 GFP-positive cells, for Vero and VeroE6/TMPRSS2 cells; the GFP intensity per well, 680 for Calu-3 cells) (b) are shown. (c) Representative images of the Calu-3 cells 681 infected with GFP-expressing viruses (100 TCID50). Areas enclosed with circles are 682 enlarged in the right panels. Assays were performed in quadruplicate

Extended Data Fig. 6. Infectivity of the P681R-bearing pseudovirus

Representative blots of SARS-CoV-2 699 full-length S and cleaved S2 proteins as well as HIV-1 p24 capsid as an internal 700 control. kDa, kilodalton. (Right) The ratio of S2 to the full-length S plus

Pseudovirus assay. The HIV-1-based reporter virus pseudotyped with the SARS-703

CoV-2 S D614G or D614G/P681R was inoculated into HOS-ACE2 cells or HOS-704

Percentages of infectivity compared to the virus pseudotyped with parental 706 S D614G (1,000 ng HIV-1 p24) in HOS-ACE2 cells are shown. The numbers on the 707 bars of the HOS-ACE2/TMPRSS2 cell data indicate the fold change versus the HOS-708 ACE2 cell data

Flow cytometry of the S-expressing cells. 714 (Left) Representative histogram of the S protein expression on the cell surface. The 715 number in the histogram indicates the mean fluorescence intensity (MFI)

The MFI of surface S on the S-expressing cells. A statistically significant difference 717 (*, P < 0.05) versus the D614G S was determined by Student's t test

To verify insertion of the mutation in the working viruses, viral RNA was 946 extracted using a QIAamp viral RNA mini kit (Qiagen, cat# 52906) and reverse 947 transcribed using SuperScript III reverse transcriptase (Thermo Fisher Scientific, 948 cat# 18080085) according to the manufacturers' protocols. DNA fragments including 949 the mutations inserted were obtained by RT-PCR using PrimeSTAR GXL DNA 950 polymerase (Takara, cat# R050A) and the following primers: WK-521 23339-23364 951 forward

Real-time RT-PCR was performed as previously described 43,45 . Briefly, 5 μl of culture 959 supernatant was mixed with 5 μl of 2 × RNA lysis buffer

40% glycerol, 0.8 U/μl recombinant RNase inhibitor 961 (Takara, cat# 2313B)] and incubated at room temperature for 10 min. RNase-free 962 water (90 μl) was added, and the diluted sample (2.5 μl) was used as the template 963 for real-time RT-PCR

AC-3'; and 966 Reverse N, 5'-CCG CCA TTG CCA GCC ATT C-3'. The copy number of viral RNA 967 was standardized with a SARS-CoV-2 direct detection RT-qPCR kit (Takara, cat# 968 RC300A). The fluorescent signal was acquired using a QuantStudio 3 Real-Time 969 PCR system

A plasmid expressing the SARS-CoV-2 S D614G/P681R mutant 976 was generated by site-directed mutagenesis PCR using pC-SARS2-S D614G 8 as 977 the template and the following primers: P681R Fw, 5'-CCA GAC CAA CAG CCG 978 GAG GAG GGC AAG GTC T-3' and P681R Rv, 5'-AGA CCT TGC CCT CCT CCG 979 GCT GTT GGT CTG G-3'. The resulting PCR fragment was digested with KpnI and 980 NotI and

HEK293T cells (1 986 × 10 6 cells) were cotransfected with 1 μg of psPAX2-IN/HiBiT 47 , 1 μg of pWPI-Luc2 47 , 987 and 500 ng of plasmids expressing parental S or its derivatives using Lipofectamine 988 3000 (Thermo Fisher Scientific, Cat# L3000015) or PEI Max (Polysciences, Cat# 989 24765-1) according to the manufacturer's protocol. At two days posttransfection, the 990 culture supernatants were harvested, centrifuged. The amount of pseudoviruses 991 prepared was quantified using the HiBiT assay as previously described 8,47 . The 992 pseudoviruses prepared were stored at -80°C until use. For the experiment, HOS-993 ACE2 cells and HOS-ACE2/TMPRSS2 cells (10,000 cells/50 μl) were seeded in 96-994 well plates and infected with 100 μl of the pseudoviruses prepared at 4 different 995 doses. At two days postinfection, the infected cells were lysed with a One-Glo 996 luciferase assay system (Promega, Cat# E6130), and the luminescent signal was 997 measured using a CentroXS3 plate reader (Berthhold Technologies) or GloMax 998 explorer multimode microplate reader 3500 (Promega). 999 1000 Western blotting 1001 Western blotting was performed as previously described 48-50

After quantification of total protein by protein assay dye 1006 (Bio-Rad, Cat# 5000006), lysates were diluted with 2 × sample buffer

Ten microliter of the samples (50 μg of total protein) 1009 were subjected to western blotting. To quantify the level of the cleaved S2 protein 1010 on virions, 900 μl of the culture medium including the pseudoviruses were layered 1011 onto 500 μl of 20% sucrose in PBS and centrifuged at 20,000 × g for 2 h at 4°C

Cat# NP0007) containing 2% β-mercaptoethanol, and the lysed 1014 virions were subjected to western blotting. For the protein detection, following 1015 antibodies were used: mouse anti-SARS-CoV-2 S monoclonal antibody

Cat# GTX632604), rabbit anti-ACTB monoclonal antibody

Cat# 711-035-152), and HRP-conjugated 1021 donkey anti-mouse IgG polyclonal antibody (Jackson ImmunoResearch, Cat# 715-1022 035-150). Chemiluminescence was detected using SuperSignal West Femto 1023 Maximum Sensitivity Substrate (Thermo Fisher Scientific, Cat# 34095) or Western 1024 BLoT Ultra Sensitive HRP Substrate (Takara, Cat# T7104A) according to the 1025 manufacturers' instruction

GE Healthcare), and the band intensity was quantified using 1027 Image Studio Lite (LI-COR Biosciences) or Image J. 1028 1029 SARS-CoV-2 S-Based Fusion Assay 1030

The SARS-CoV-2 S-based fusion assay was performed as previously described 43

On day 3 (24 h posttransfection), 1041 16,000 effector cells were detached and reseeded into 96-well black plates 1042 (PerkinElmer, Cat# 6005225), and target cells were reseeded at a density of 1043 1,000,000 cells/2 ml/well in 6-well plates. On day 4 (48 h posttransfection), target 1044 cells were incubated with EnduRen live cell substrate (Promega, Cat# E6481) for 3 1045 h and then detached, and 32,000 target cells were applied to a 96-well plate with 1046 effector cells. RL activity was measured at the indicated time points using a Centro 1047 XS3 LB960 (Berthhold Technologies). The S proteins expressed on the surface of 1048 effector cells were stained with rabbit anti-SARS-CoV-2 S monoclonal antibody 1049 (GeneTex, Cat# GTX635654) and APC-conjugated goat anti-rabbit IgG polyclonal 1050 antibody (Jackson ImmunoResearch, Cat# 111-136-144). Normal rabbit IgG 1051 (SouthernBiotech, Cat# 0111-01) was used as a negative control. Expression levels 1052 of surface S proteins were analyzed using a FACS Canto II

Mathematical Modeling for Fusion Velocity Quantification 1057 The following cubic polynomial regression model was employed to fit each of time-1058 series datasets (Fig

The initial velocity of cell fusion was estimated from the derivative of the fitted cubic 1061 curve. 1062 1063 Neutralisation Assay 1064 Virus neutralisation assay was performed on HOS-ACE2/TMPRSS2 cells using the 1065 SARS-CoV-2 S pseudoviruses expressing luciferase (see "Pseudovirus Assay" 1066 above). The viral particles pseudotyped with D614G S or D614G/P681R S were 1067 incubated with serial dilution of heat

The 1069 pseudoviruses without sera and NAbs were also included. Then, the 80 μl mixture 1070 of pseudovirus and sera/NAbs was added into HOS-ACE2/TMPRSS2 cells (10,000 1071 cells/50 μl) in a 96-well white plate and the luminescence was measured as 1072 described above (see "Pseudovirus Assay" above)

For the cell-cell fusion neutralisation assay, effector cells of the S-based 1075 fusion assay (i.e., S-expressing cells) were incubated with the serially diluted 1076 neutralizing antibodies targeting RBD (clones 8A5, 4A3 and CB6; Elabscience) at 1077 37°C for 1 h. Then, target cells were applied and performed the S-based fusion 1078 assay as described above (see

sublineages possibly due to 212 undetermined nucleotides in the genome. To infer 823 epidemiology of the B.1.617 lineage ( Fig. 1b-1f One day prior to infection, Vero cells (10,000 cells), VeroE6/TMPRSS2 cells (10,000 875 cells) and Calu-3 cells (10,000 cells) were seeded into a 96-well plate. SARS-CoV-876 2 was inoculated and incubated at 37°C for 1 h. The infected cells were washed, and 877 180 µl of culture medium was added. The culture supernatant (10 µl) was harvested 878 at indicated time points and used for real-time RT-PCR to quantify the viral RNA 879 copy number. To monitor the syncytia formed in infected cell culture, the bright-field 880 photos were obtained using ECLIPSE Ts2 (Nikon). The size of floating syncytia was 881 measured by "quick selection tool" in Photoshop CS5 (Adobe) as pixel, and the area 882 of floating syncytia was calculated from the pixel value. As for the GFP-expressing 883 recombinant viruses (Extended Data Fig. 4b, c) , the bright-field and green 884 fluorescence photos were obtained using an All-in-One Fluorescence microscope 885 BZ-X800 (Keyence) at the indicated time points, and the GFP-fluorescence intensity 886 was analyzed by a BZ-X800 Analyzer (Keyence). 887 888Immunofluorescence Staining 889One day prior to infection, VeroE6/TMPRSS2 cells (200,000 cells) were seeded on 890 the coverslips put in 12-well plate and were infected with SARS-CoV-2 (2,000 891 TCID50). At 48 hours postinfection, the cells were fixed with 4% paraformaldehyde 892 in phosphate buffer saline (PBS) (Nacalai Tesque, Cat# 09154-85) for 10 min at 893 room temperature. The fixed cells were permeabilized with 0.1% Triton X-100 in PBS 894for 10 min, blocked with 10% FBS in PBS for overnight at 4°C, and then stained 895 using mouse anti-SARS-CoV-2 N monoclonal antibody (GeneTex, Cat# 896